Latent TGF beta 3/Latent TGFB3 Protein, Human (Biotinylated, HEK293, His)

Latent transforming growth factor beta-3 (TGF-beta-3) preprotein serves as a precursor to latency-associated peptide (LAP) and active TGF-beta-3 chains, which serve as regulatory and functional subunits. It plays a crucial role in maintaining the latent state of TGF-β-3 within the extracellular matrix. Latent TGF beta 3/Latent TGFB3 Protein, Human (Biotinylated, HEK293, His) is the recombinant human-derived Latent TGF beta 3/Latent TGFB3 protein, expressed by HEK293 , with N-His labeled tag.

Latent Transforming growth factor beta-3 (TGF-beta-3) proprotein serves as the precursor for both the Latency-associated peptide (LAP) and the active TGF-beta-3 chains, acting as the regulatory and functional subunits, respectively. It plays a vital role in maintaining the latent state of TGF-beta-3 within the extracellular matrix. Through non-covalent association with TGF-beta-3, Latent TGF-beta-3 actively regulates the activation process by interacting with key 'milieu molecules' such as LTBP1 and LRRC32/GARP. These interactions contribute to the controlled activation of TGF-beta-3, with LTBP1 and LRRC32/GARP acting as crucial components in this regulatory mechanism. Additionally, interaction with integrins induces structural changes in the Latency-associated peptide chain, leading to the subsequent release of active TGF-beta-3. This sophisticated molecular interplay underscores the pivotal role of Latent TGF-beta-3 in orchestrating the regulated activation of TGF-beta-3 in various physiological contexts.

Human

HEK293

N-8*His

P10600-1 (L24-S412)

7043  [NCBI]

Full Length of Isoform-1 Mature Protein

Biotin

The biotin is covalently conjugated to the primary amine groups of the protein using chemical labeling methods.

LSTCTTLDFGHIKKKRVEAIRGQILSKLRLTSPPEPTVMTHVPYQVLALYNSTRELLEEMHGEREEGCTQENTESEYYAKEIHKFDMIQGLAEHNELAVCPKGITSKVFRFNVSSVEKNRTNLFRAEFRVLRVPNPSSKRNEQRIELFQILRPDEHIAKQRYIGGKNLPTRGTAEWLSFDVTDTVREWLLRRESNLGLEISIHCPCHTFQPNGDILENIHEVMEIKFKGVDNEDDHGRGDLGRLKKQKDHHNPHLILMMIPPHRLDNPGQGGQRKKRALDTNYCFRNLEENCCVRPLYIDFRQDLGWKWVHEPKGYYANFCSGPCPYLRSADTTHSTVLGLYNTLNPEASASPCCVPQDLEPLTILYYVGRTPKVEQLSNMVVKSCKCS

Approximately 45-60 kDa, based on SDS-PAGE under reducing conditions, due to the glycosylation.

≥ 95%, as determined by reducing SDS-PAGE.

<1 EU/μg, determined by LAL method.